Positive benefits of blended diet: weighing in on gastrointestinal dystonia

Rebecca Poole1, Michelle Brooks1, Jacqueline Hay2, Konstantinos Gerasimidis3, Sarah Bremer2, Tracey Cardigan2, Hazel Duncan4, Gillian Smith5, Elaine Buchanan2, Simon Fraser6, James Andrews7, Timothy Bradnock7, Rania Kronfli7, Gregor Walker7, Christina McGuckin1, Diana Flynn1, Andrew Barclay2

1Royal Hospital for Children, Paediatric Gastroenterology, Glasgow, 2Royal Hospital for Children, Paediatric Dietsetics, Glasgow, 3University of Glasgow, School of Medicine, Dentistry and Nursing, Glasgow, 4Uneriversity Hospital Crosshouse, Paediatric Dietsetics, Kilmarnock, 5University Hospital of Wishaw, Paediatric Dietsetics, Wishaw, 6Royal Hospital for Children, Paediatric Pharmacy, Glasgow, 7Royal Hospital for Children, Paediatric Surgery, Glasgow

Introduction
Children with severe neurodisability and tone disorders can present with debilitating symptoms and declining growth. Gastrointestinal dystonia (GID) describes the clinical manifestations of: pain behaviour; hypertonicity; retching; vomiting; vagal phenomena; abdominal distension and straining attributable to the GI tract in the context of severe neurodisability.1 Blended diet (BD) has an emerging role in the nutritional management of patients with neurodisability, however we are unaware of data pertaining to BD specifically in patients with GID.

Aim
A tertiary centre review of outcomes of patients with GID receiving BD.

Method
Patients who commenced BD between 07/2017 and 02/2020 were identified from prospectively gathered complex enteral nutrition (CEN) and specialist dietetic databases. BD was initiated with specialist paediatric dietetic support within the CEN clinic and other clinics. Data gathered included: demographics; primary diagnosis; enteral feeding plan; fundoplication; weight standard deviation z score at 0, 6, 12 and 18 months prior to and from commencing BD; medications at 0, 12 and 18 months; reasons if BD discontinued; parenteral nutrition (PN) requirement.

Results
29 children met criteria for GID and commenced BD1. 18 were male. 14 had a fundoplication. Feeding method prior to BD: gastric bolus 17; gastric continuous 8; jejunal 4. Mean age BD commenced was 7 years. Follow up ranged 8 to 40 months. 25 patients continue BD to date. 4 discontinued BD within 1-2 months citing increased GI symptoms (3) or device blockage(1).

Of the 25 who continue BD, median weight z scores declined from -1.77 at 12 months prior to BD, -1.86 at 6 months prior, -1.94 at 0 months, then rose to -1.54 at 12 months, and -1.40 at 18 months. Mean weight z scores were maintained at -1.97 (CI -0.85 to -3.09) at 0 months, -1.97 (CI -0.27 to -3.02) at 12 months and -1.79 (CI -0.34 to -3.25) at 18 months [fig1]. This trend was more significant in a subset of 6 patients, z score -2.06 (CI -1.46 to -2.67) at 0 months, -1.13 (CI -0.59 to -1.67) at 12 months (p = 0.018) and -0.84 (CI -0.46 to -1.21) at 18 months (p = 0.003) [fig2].

10 of the 25 receive their full dietary requirements from BD. Figure 3 shows the distribution of % of diet from BD. Those progressing to full BD experienced an improvement in mean z score [fig 4].

8 of the 25 discontinued one GI medication, 5 discontinued two GI medications. Number of tone or sedating medications: 5 reduced; 18 unchanged; 2 increased and commenced nabilone. No patients received PN during the study.

Figure 3: % of dietary requirements from BD

Full
>75%
75-50%
25-49%
<25%

Figure 4: Mean weight z scores by % of dietary requirements from BD

Conclusion
GID represents the severest end point of gastrointestinal symptoms in neurodisability, with progressive decline often a feature. Our data show children with GID receiving BD continue to track their weight trajectory, whilst some experience significantly improved growth. No patients required trial on PN during the study. The authors advocate for BD’s role in minimizing the need for invasive treatments in GID whilst addressing symptoms and maintaining nutritional status and growth superiorly to formula feeds alone. Improvements in symptomatology and quality of life will be better described by prospective survey of patients commencing BD for GID. The authors are currently gathering these data.

References
1 McConnell N, et al JPGN;66(supp2):1002;2018
2 Hay J, et al (presented BSPGHAN 2020)